Author:
Phillips Anna E.,Tohon Zilahatou,Dhanani Neerav A.,Sofo Boubacar,Gnandou Issa,Sidikou Boubacar,Noma Adamou Garba,Madougou Bassirou,Alto Oumarou,Sebangou Hannatou,Halilou Kader M.,Andia Roumanatou,Garba Amadou,Fenwick Alan,Hamidou Amina A.
Abstract
Abstract
Background
The Schistosomiasis Consortium for Operational Research and Evaluation (SCORE) coordinated a five-year study implemented in several countries, including Niger, to provide an evidence-base for programmatic decisions regarding cost-effective approaches to preventive chemotherapy for schistosomiasis control.
Methods
This was a cluster-randomised trial investigating six possible combinations of annual or biannual community-wide treatment (CWT), school-based treatment (SBT), and holidays from mass treatment over four years. The most intense arm involved two years of annual CWT followed by 2 years of biannual CWT, while the least intensive arm involved one year of annual SBT followed by a year without treatment and two more years of annual SBT. The primary outcome of interest was prevalence and intensity of Schistosoma haematobium among 100 children aged 9–12 years sampled each year. In addition, 100 children aged 5–8 years in their first year of school and 50 adults (aged 20–55 years) were tested in the first and final fifth year of the study.
Results
In total, data were collected from 167,500 individuals across 225 villages in nine districts within the Niger River valley, Western Niger. Overall, the prevalence of S. haematobium decreased from baseline to Year 5 across all study arms. The relative reduction of prevalence was greater in biannual compared with annual treatment across all arms; however, the only significant difference was seen in areas with a high starting prevalence. Although adults were not targeted for treatment in SBT arms, a statistically significant decrease in prevalence among adults was seen in moderate prevalence areas receiving biannual (10.7% to 4.8%) SBT (P < 0.001). Adults tested in the annual SBT group also showed a decrease in prevalence between Year 1 and Year 5 (12.2% to 11.0%), but this difference was not significant.
Conclusions
These findings are an important consideration for schistosomiasis control programmes that are considering elimination and support the idea that scaling up the frequency of treatment rounds, particularly in areas of low prevalence, will not eliminate schistosomiasis. Interestingly, the finding that prevalence decreased among adults in SBT arms suggests that transmission in the community can be reduced, even where only school children are being treated, which could have logistical and cost-saving implications for the national control programmes.
Funder
Bill and Melinda Gates Foundation
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Parasitology
Reference50 articles.
1. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis. 2006;6:411–25.
2. WHO. Update on the global status of implementation of preventive chemotherapy (PC). Geneva: World Health Organization; 2019. https://www.who.int/neglected_diseases/preventive_chemotherapy/PC_Update.pdf. Accessed 14 Sep 2020.
3. Lai Y-S, Biedermann P, Ekpo UF, Garba A, Mathieu E, Midzi N, et al. Spatial distribution of schistosomiasis and treatment needs in sub-Saharan Africa: a systematic review and geostatistical analysis. Lancet Infect Dis. 2015;15:927–40.
4. Clements A, Garba A, Sacko M, Touré S, Dembelé R, Landouré A, et al. Mapping the probability of schistosomiasis and associated uncertainty. West Africa Emerg Infect Dis. 2008;14:1629–32.
5. Garba A, Touré S, Dembelé R, Bosque-Oliva E, Fenwick A. Implementation of national schistosomiasis control programmes in West Africa. Trends Parasitol. 2006;22:322–6.